Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer:: Comparison with serum levels of sialic acid, TPS and Cyfra 21-1

被引：14
作者：
de Castro, Javier [2 ]
Rodriguez, Marina C.
Martinez-Zorzano, Vicenta S. [3 ]
Hernandez-Hernandez, Angel [1 ]
Llanillo, Marcial [1 ]
Sanchez-Yaguee, Jesus [1 ]
机构：
[1] Univ Salamanca, Dept Biochem & Mol Biol, Edificio Departmental, Lab 106, Salamanca 37007, Spain
[2] Santisima Trinidad Fdn Hosp, Serv Radiol, Salamanca, Spain
[3] Univ Vigo, Dept Biochem Genet & Immunol, Vigo 36310, Spain
来源：
CANCER INVESTIGATION | 2008年 / 26卷 / 04期
关键词：
tumor markers; non-small cell lung cancer; fatty acids; sialic acids; cytokeratins; erythrocyte; platelet;
D O I：
10.1080/07357900701788114
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The phospholipid fatty acid profiles of erythrocytes and platelets from fifty patients with advanced non-small cell lung cancer were investigated using gas chromatography/mass spectrometry, followed by "ROC" curves analysis to gain novel biomarker information. Sialic acid and cytokeratins were also examined. Potentially useful fatty acid markers: Erythrocytes: phosphatidylcholine, 18:2n6 and 20:4n6; phosphatidylethanolamine, 22:4n6 and 22:6n3 + 24:1n9. Platelets: phosphatidylcholine, 22.0; phosphatidylethanolamine, 22:5n3 + 24:0. At the cut-off value to obtain maximum accuracy, the best biomarkers were found in platelets: phosphatidylserine + phosphatidylinositol (PS + PI), 21:0; sphyngomyelin: 20:1n9 and 22:1n9. All these fatty acids showed similar/higher diagnostic yields than the commonly used markers sialic acid or cytokeratins.
引用
收藏
页码：407 / 418
页数：12
相关论文
共 43 条
[1]   Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions [J].
Alatas, F ;
Alatas, Ö ;
Metintas, M ;
Çolak, Ö ;
Harmanci, E ;
Demir, S .
LUNG CANCER, 2001, 31 (01) :9-16
[2]   METHODS FOR QUANTITATIVE ESTIMATION OF N-ACETYLNEURAMINIC ACID AND THEIR APPLICATION TO HYDROLYSATES OF SIALOMUCOIDS [J].
AMINOFF, D .
BIOCHEMICAL JOURNAL, 1961, 81 (02) :384-&
[3]  
Buccheri G, 2001, Expert Rev Mol Diagn, V1, P315, DOI 10.1586/14737159.1.3.315
[4]   Lung tumor markers of cytokeratin origin: an overview [J].
Buccheri, G ;
Ferrigno, D .
LUNG CANCER, 2001, 34 :S65-S69
[5]   A medical bioinformatics approach for metabolic disorders:: Biomedical data prediction, modeling, and systematic analysis [J].
Chen, M ;
Hofestädt, R .
JOURNAL OF BIOMEDICAL INFORMATICS, 2006, 39 (02) :147-159
[6]   Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma [J].
de Castro, Javier ;
Hernandez-Hernandez, Angel ;
Rodriguez, Marina C. ;
Sardina, Jose L. ;
Llanillo, Marcial ;
Sanchez-Yague, Jesus .
PLATELETS, 2007, 18 (01) :43-51
[7]   Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanced non-small cell lung cancer [J].
de Castro, Javier ;
Hernandez-Hernandez, Angel ;
Rodriguez, Marina C. ;
Llanillo, Marcial ;
Sanchez-Yague, Jesus .
CANCER INVESTIGATION, 2006, 24 (04) :339-345
[8]   Clinical significance of preoperative serum sialic acid levels in colorectal cancer:: Utility in the detection of patients at high risk of tumor recurrence [J].
Feijoo-Carnero, C ;
Rodríguez-Berrocal, FJ ;
de la Cadena, MN ;
Ayude, D ;
de Carlos, A ;
Martínez-Zorzano, VS .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2004, 19 (01) :38-45
[9]  
Fischer AR, 2004, LUNG CANCER, V45, pS151, DOI 10.1016/j.lungcan.2004.07.000
[10]  
GORNALL AG, 1949, J BIOL CHEM, V177, P751
12345